NorthWest Biotherapeutics Inc (NWBO)

[Lykiri]

That’s a very good point — it really does look like the MHRA is using DCVax-L not just as a single product review, but as a pilot case to refine the regulatory framework for digitally managed, autologous cell therapies.

The recent CGT Catapult–Autolomous white paper (Oct 2025) is a perfect example of this “system-building” approach. Although it focused on a CAR-T process rather than a dendritic cell therapy, it validated — in a real MHRA-licensed environment — that fully digital GMP manufacturing via the autoloMATE™ platform can ensure full MHRA/EMA/FDA-compliant data integrity, enable end-to-end traceability, cut documentation-review time by 65%, and eliminate paper entirely.

Since DCVax-L is manufactured using this same digital infrastructure at Sawston, it’s reasonable to think the MHRA wanted this government-backed validation in place before concluding its assessment — not because there are regulatory obstacles, but because DCVax-L serves as the first real-world test case for embedding these digital manufacturing standards into the UK’s regulatory framework. In that sense, murcidencel/DCVax-L isn’t just a product under review — it’s the prototype guiding how future personalised cell and gene therapies will be regulated. IMO.
https://ct.catapult.org.uk/news/cgt-catapult-and-autolomous-showcase-benefits-of-digital-technologies-in-advanced-therapy-manufacturing